Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473379 | 0.77 | RXFP1 (0.49) | BRD4RXFP1PDE2APDE3BPDE3A | |
| SCHEMBL16739018 | 0.76 | RXFP1 (0.40) | BRD4RXFP1PDE2APDE3BPDE3A | |
| SCHEMBL7884503 | 0.73 | RXFP1 (0.47) | RXFP1PDE2APDE3BPDE3ACSNK2A2 | |
| SCHEMBL626494 | 0.71 | RXFP1 (0.43) | BRD4RXFP1TP53PDE2APDE3B | |
| SCHEMBL16738871 | 0.71 | RXFP1 (0.40) | BRD4RXFP1PDE2APDE3BPDE3A | |
| SCHEMBL194512 | 0.70 | DAO (0.69) | BRD4RXFP1LMNADAOMAPT | |
| SCHEMBL16739006 | 0.69 | ALDH1A1 (0.41) | BRD4RXFP1PDE2APDE3BPDE3A | |
| SCHEMBL16739014 | 0.69 | BRD4 (1.00) | BRD4BRD2 | |
| SCHEMBL4589419 | 0.68 | CA12 (0.53) | LMNAKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18149218 | 0.68 | ALOX5 (0.39) | BRD4TP53MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-9918990-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399640-B2 | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2015081203-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014418-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885RXFP1 4144/4885TP53 381/4885 |
| US-20150148342-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | BRD4 4/4885RXFP1 4144/4885TP53 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.